Get the Stockscreener App
9.88
5.44%
0.51
Avalo Therapeutics Inc stock is traded at $9.88, with a volume of 148.46K.
It is up +5.44% in the last 24 hours and up +53.89% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$9.37
Open:
$9.32
24h Volume:
148.46K
Relative Volume:
0.85
Market Cap:
$129.95M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.0028
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
+9.53%
1M Performance:
+53.89%
6M Performance:
+17.06%
1Y Performance:
+16.92%
1-Day Range:
$9.18
$10.17
1-Week Range:
$8.41
$10.17
52-Week Range:
$3.39
$16.00
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
9.88 | 119.16M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Is Avalo Therapeutics Inc. Forming a Bottom PatternGap Up & Growth-Oriented Investment Plans - classian.co.kr
Is Avalo Therapeutics Inc. forming a bottoming baseJuly 2025 News Drivers & Safe Entry Trade Signal Reports - Newser
News impact scoring models applied to Avalo Therapeutics Inc.July 2025 Outlook & Growth Focused Entry Reports - Newser
Quantitative breakdown of Avalo Therapeutics Inc. recent movePortfolio Value Summary & Daily Stock Trend Watchlist - Newser
Should you hold or exit Avalo Therapeutics Inc. nowPortfolio Update Summary & Entry Point Strategy Guides - Newser
Will Avalo Therapeutics Inc. benefit from macro trendsTrade Volume Summary & High Accuracy Trade Signal Alerts - Newser
How to track smart money flows in Avalo Therapeutics Inc.Trade Analysis Summary & Real-Time Buy Zone Alerts - Newser
What institutions are buying Avalo Therapeutics Inc. stock nowTrade Risk Summary & Fast Entry Momentum Alerts - beatles.ru
Can swing trading help recover from Avalo Therapeutics Inc. lossesQuarterly Growth Report & Long-Term Capital Growth Ideas - Newser
Avalo Therapeutics: Speculative Buy Ahead of AVTX-009's LOTUS Results - AInvest
Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009’s LOTUS Results (NASDAQ:AVTX) - Seeking Alpha
How to forecast Avalo Therapeutics Inc. trends using time seriesJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - Newser
Is Avalo Therapeutics Inc. forming a reversal patternMarket Activity Summary & AI Driven Stock Price Forecasts - Newser
Avalo Therapeutics Inc. stock outlook for YEARShort Setup & Real-Time Volume Triggers - Newser
Avalo Therapeutics Inc. stock momentum explainedCPI Data & Stock Portfolio Risk Management - Newser
Developing predictive dashboards with Avalo Therapeutics Inc. dataJuly 2025 PostEarnings & Weekly Watchlist for Hot Stocks - Newser
Using RSI to spot recovery in Avalo Therapeutics Inc.Weekly Stock Report & Short-Term High Return Ideas - Newser
Buy Signal for Avalo Therapeutics Inc. Stock Key Technical Indicators to WatchJuly 2025 WrapUp & Fast Gain Swing Alerts - Newser
Chart based exit strategy for Avalo Therapeutics Inc.July 2025 Trade Ideas & Smart Money Movement Alerts - Newser
Avalo Therapeutics Initiated with Overweight Rating by Cantor Fitzgerald - AInvest
Can Avalo Therapeutics Inc. recover in the next quarterWeekly Trend Summary & Target Return Focused Picks - Newser
Avalo Therapeutics Gains as Cantor Fitzgerald Initiates Coverage with Bullish View on Lead Asset AVTX-009. - AInvest
Avalo stock gains after Cantor bullish view (AVTX:NASDAQ) - Seeking Alpha
Cantor Fitzgerald initiates Avalo Therapeutics stock with Overweight rating - Investing.com
Cantor Fitzgerald Initiates Avalo Therapeutics at Overweight - MarketScreener
Avalo Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks
Should you wait for a breakout in Avalo Therapeutics Inc.Forecast Cut & Free Technical Pattern Based Buy Signals - Newser
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Is Avalo Therapeutics Inc. reversing from oversold territoryEarnings Summary Report & Growth Oriented Trade Recommendations - Newser
Avalo Therapeutics Reports Q2 2025 Financial Results - MSN
Avalo Therapeutics Inc.’s Beta Climbs After Market VolatilityEarnings Trend Report & Weekly Market Pulse Updates - sundaytimes.kr
Avalo Therapeutics: Oppenheimer Maintains Buy Rating with $35 Price Target - AInvest
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Almenoff June Sherie | Director |
Nov 12 '24 |
Buy |
12.50 |
500 |
6,250 |
500 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):